173 related articles for article (PubMed ID: 36436019)
1. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
Cui H; Lan Z; Zou KL; Zhao YY; Yu GT
Cancer Immunol Immunother; 2023 May; 72(5):1315-1326. PubMed ID: 36436019
[TBL] [Abstract][Full Text] [Related]
2. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
3. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
4. Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma.
Pang X; Fan HY; Tang YL; Wang SS; Cao MX; Wang HF; Dai LL; Wang K; Yu XH; Wu JB; Tang YJ; Liang XH
PLoS One; 2020; 15(2):e0229089. PubMed ID: 32092078
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
6. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells and plasmacytoid dendritic cells are associated with oncogenesis of oral squamous cell carcinoma.
Kouketsu A; Haruka S; Kuroda K; Hitoshi M; Kensuke Y; Tsuyoshi S; Takahashi T; Hiroyuki K
J Oral Pathol Med; 2023 Jan; 52(1):9-19. PubMed ID: 36380437
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
9. Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.
Ryzhov SV; Pickup MW; Chytil A; Gorska AE; Zhang Q; Owens P; Feoktistov I; Moses HL; Novitskiy SV
J Immunol; 2014 Sep; 193(6):3155-64. PubMed ID: 25127858
[TBL] [Abstract][Full Text] [Related]
10. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
[TBL] [Abstract][Full Text] [Related]
11. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
[TBL] [Abstract][Full Text] [Related]
12. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
13. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
15. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
16. CD73 is associated with poor prognosis in HNSCC.
Ren ZH; Lin CZ; Cao W; Yang R; Lu W; Liu ZQ; Chen YM; Yang X; Tian Z; Wang LZ; Li J; Wang X; Chen WT; Ji T; Zhang CP
Oncotarget; 2016 Sep; 7(38):61690-61702. PubMed ID: 27557512
[TBL] [Abstract][Full Text] [Related]
17. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.
He JY; Huo FY; Tang HC; Liu B; Bu LL
Int Rev Cell Mol Biol; 2023; 375():33-92. PubMed ID: 36967154
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma.
Dar AA; Patil RS; Pradhan TN; Chaukar DA; D'Cruz AK; Chiplunkar SV
Cancer Immunol Immunother; 2020 Jun; 69(6):1071-1086. PubMed ID: 32103293
[TBL] [Abstract][Full Text] [Related]
20. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]